Physician profile
Andrea Martin
NPI 1740523885
$16,851.89
in general payments reported to CMS, 2019-2025
75 companies · $2,880 in 2025
The $2,880 reported for 2025 was more than what 96% of Physician Assistant providers received nationally (typical 2025 total: $183).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $3,156 · 2022: $3,521 · 2023: $3,430 · 2024: $3,865 · 2025: $2,880.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $10K · Education: $2.10.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $10,172.91 |
| Education | $2.10 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $2,900.87 | 2021-2025 | |
| Novo Nordisk INC | $1,611.79 | 2021-2025 | Wegovy, Rybelsus, Ozempic |
| Lilly USA, LLC | $1,105.72 | 2021-2025 | Zepbound, Mounjaro, Jardiance |
| Antares Pharma, INC. | $792.25 | 2021-2025 | Xyosted, Nocdurna, Tlando |
| Ucb, INC. | $709.52 | 2024-2025 | Bimzelx |
| Amgen INC. | $557.48 | 2021-2025 | Repatha, Otezla, Repatha |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $519.72 | 2021-2025 | Xifaxan, Trulance, Ibschek |
| Tris Pharma INC | $455.71 | 2022-2025 | Dyanavel Xr |
| Axsome Therapeutics, INC. | $447.39 | 2023-2025 | Auvelity, Sunosi, Symbravo |
| Neos Therapeutics, Lp | $442.15 | 2021-2024 | Adzenys Xr-Odt, Cotempla Xr-Odt |
| Bausch Health US, LLC | $428.53 | 2021-2024 | Aplenzin, Wellbutrin |
| Bayer Healthcare Pharmaceuticals INC. | $374.58 | 2021-2025 | |
| Novartis Pharmaceuticals Corporation | $349.19 | 2021-2025 | |
| Abbott Laboratories | $348.15 | 2021-2024 | Freestyle Libre 3, Freestyle Libre 2 |
| Pfizer INC. | $339.64 | 2021-2025 |
Show all 75 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Andrea Martin listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.